Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Lumpectomy as effective as mastectomy in young breast cancer patients
  • News

Lumpectomy as effective as mastectomy in young breast cancer patients

  • 13 May 2022
  • Janet Fricker
Lumpectomy as effective as mastectomy in young breast cancer patients
Total
0
Shares
0
0
0
0
0

Women under 40 with non-metastatic breast cancer experience similar survival regardless of whether they are treated with mastectomy or lumpectomy. The abstract presented at the American Society of Breast Surgeons annual meeting, held in Las Vegas, April 2022, showed that this finding held true across hormone receptor (HR) and HER2 subtypes. The study represents one of the largest ever to explore outcomes for breast cancer surgery in younger patient populations.

“The results are particularly significant because younger women are increasingly being diagnosed with breast cancer, despite low rates overall, and a growing number are undergoing mastectomy and even prophylactic bilateral mastectomy rather than breast conserving surgery,” says lead author Christine Pestana, from Levine Cancer Institute, Winston Salem, North Carolina.

In Western populations around 7% of breast cancers are diagnosed among women aged 40 years or younger, with early age-of-onset known to increase risk of contralateral breast cancer and local and distant recurrence, as well as subsequent mortality. Due to known worse clinical outcomes, young women with breast cancer have a tendency to equate more aggressive treatment with improved survival. But in making treatment decisions, says Pestana, there may be a tendency to disregard the consequences of mastectomy, including greater risks of infection, chronic pain, and the need for subsequent multiple reconstruction procedures.

For the study, Pestana and colleagues performed a retrospective chart review of 885 women under the age of 40, who were included in the Young Women’s Database at a single institution, and who were diagnosed with non-metastatic breast cancer, between 2010 and 2019, and were treated surgically. Due to missing data, 294 subjects were excluded, leaving 591 patients to be included in the analysis. Along with the type of surgery, demographic data, and information on stage, tumour grade, and the use of hormonal and systemic therapy were collected. Univariable and multivariable Cox proportional hazard analyses were then performed to determine whether patient, disease, or treatment factors were associated with increased risk of death. The median age for the cohort was 37 years, median time to follow up was 67 months. Molecular subtypes included were HR+/HER2‒ (n=315), HR+/HER2+ (n=123), triple negative (n=114), and HR‒/HER2+ (n=39).

Results showed that:

  • At the time of follow up, 12% of patients (n=72) had died.
  • Overall, treatment with mastectomy vs lumpectomy had no impact on survival (logrank P=0.2652).
  • Use of mastectomy vs breast conservation had no impact on survival in any of the hormone receptor or HER2 subtypes.
  • Of the HR+/HER2‒ group, 85.4% took antioestrogen therapy. Only an absence of hormone therapy appeared to be significant for survival, with an almost three-fold increased risk of death for patients who did not take hormone therapy vs those who did.
  • African‒American ethnicity was associated with a 5.7-fold increased risk of death in women with triple negative disease.

“Overall survival does not differ based upon type of surgery in younger patients with breast cancer,” concluded the authors in the conference abstract. “Counselling regarding outcomes is important, especially in reducing unnecessary morbidity from surgical procedures that are not indicated.”

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • breast cancer
  • breast conserving surgery
  • HER2
  • hormone receptors
  • lumpectomy
  • mastectomy
  • survival
  • young women
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • News

Multi organ chip could facilitate personalised cancer therapy 

  • 12 May 2022
  • Janet Fricker
View Post
Next Article
  • Articles
  • Biology basic

What can we expect from mRNA cancer vaccines?

  • 13 May 2022
  • Sophie Fessl
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Yeva Margaryan
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Yeva Margaryan
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.